#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this evidence summary to counsel patients with depression, anxiety, or PTSD who may be considering cannabis as treatment, since current evidence does not support its use for these common conditions. This finding helps providers distinguish between conditions where cannabis shows therapeutic promise (such as seizure disorders) and those where it lacks evidence, enabling more informed treatment planning. Patients should be directed toward evidence-based interventions for mood and anxiety disorders rather than relying on unproven cannabis therapies that may delay necessary care.
A recent evidence review found insufficient clinical data to support the use of medicinal cannabis for depression, anxiety, or post-traumatic stress disorder, despite these conditions being among the most common reasons patients seek cannabis treatment. While the review acknowledges that cannabis may have demonstrated benefit in specific conditions such as chemotherapy-induced nausea, chronic pain, and certain seizure disorders, the evidence base for neuropsychiatric indications remains limited by small sample sizes, heterogeneous study designs, and the predominance of observational rather than randomized controlled trials. This gap between patient demand and clinical evidence is particularly concerning given the rising prevalence of mental health conditions and the growing normalization of cannabis use following legalization in many jurisdictions. Clinicians should be cautious about recommending cannabis as a first-line or evidence-based treatment for mood and anxiety disorders, where established pharmacotherapies and psychosocial interventions have robust supporting data. Patients presenting with depression, anxiety, or PTSD who are considering or already using cannabis should be counseled about the lack of proven efficacy and encouraged to pursue guideline-concordant treatments while ongoing research clarifies cannabis’s potential role in mental health care.
“When patients come to me with depression, anxiety, or PTSD asking about cannabis, I tell them the same thing I tell them about any unproven treatment: the evidence simply isn’t there yet, and using it as a first-line therapy means delaying interventions we know work. That said, I don’t dismiss cannabis outright for every patient, because the research landscape is evolving and some individuals report subjective benefit, but I won’t pretend that clinical evidence supports it for these conditions when it doesn’t.”
🧠 The absence of robust evidence for cannabis efficacy in depression, anxiety, and PTSD should inform clinical decision-making in these common conditions, particularly given the high burden of disease and availability of established pharmacotherapies with demonstrated benefit. While cannabinoid research continues to evolve and some patients report subjective symptom relief, clinicians should be cautious about recommending cannabis as a first-line or alternative treatment for these psychiatric disorders without stronger evidence, especially considering potential risks such as cognitive effects, dependence, and possible worsening of psychotic symptoms in vulnerable populations. The distinction between emerging evidence in specific conditions like epilepsy and the current evidence gap for mood and anxiety disorders is clinically important and should guide patient conversations about realistic therapeutic expectations. Practitioners can acknowledge patient interest in cannabis while recommending evidence-based treatments like psychotherapy or antidepressants, and consider cannabis only within shared decision-making frameworks that account for individual risk factors,
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: